SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (882)5/26/1999 11:45:00 PM
From: Michael Brody  Read Replies (1) | Respond to of 2344
 
WW jr.,

I too would appreciate further info. especially on point number 3.
Just how does the company plan to increase their exposure in
a more agressive way ? Many people agree that this is one of the
important missing elements with BIOM. If the story is truly as
good as most everyone seems to think it is why not make it
known ? What specific steps were proposed ? Any word on a
N.Y. Times article ?



To: Jim Oravetz who wrote (882)5/27/1999 12:14:00 PM
From: William Whitehead Jr.  Read Replies (2) | Respond to of 2344
 
Jim:

I would say that at least 75% of the questions dealt with the Theratope study in one way or another, such as ramp-up period to enroll the 900 subjects, aspects of research study, FDA requirements re: time-line of disease progression etc.

Remaining questions dealt with shareholder value - cash flow requirements etc.

Whitey,


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News